Skip to main content
Observe Medical logo

Observe Medical — Investor Relations & Filings

Ticker · OBSRV ISIN · NO0010865009 LEI · 9845005F38B74FFJ1B65 Euronext Expand Manufacturing
Open in API
Filings indexed 643 across all filing types
Latest filing 2024-04-30 Annual Report
Country NO Norway
Listing Euronext Expand OBSRV

About Observe Medical

https://observemedical.com/

Observe Medical is a medical technology company that develops, markets, and sells innovative medtech products for the global market. The company is committed to improving patient welfare and outcomes, increasing clinical data accuracy, and promoting positive health economics. It is building a scalable medtech platform that combines a portfolio of proprietary products with strategic partnerships, leveraging its manufacturing, development, regulatory, and commercial capabilities to bring new technologies to market.

Recent filings

Filing Released Lang Actions
Observe Medical Annual Report for 2023
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Observe Medical for the fiscal year 2023. It includes a table of contents, letter from the CEO, board of directors' report, consolidated financial statements, auditor's report, and key figures. It is clearly the official annual report of the company, not an announcement or a summary. FY 2023
2024-04-30 English
Observe Medical Annual Report for 2023
Report Publication Announcement Classification · 98% confidence The document explicitly states in the title and body that it is the "Observe Medical Annual Report for 2023". However, the document length is very short (2252 characters) and the content primarily serves as an announcement, stating that the Annual Report "is attached to this notice and available on the Company's website". According to Rule #2 (The 'MENU VS MEAL' Rule), when a short document announces the publication of a full report (like an Annual Report), it should be classified as a Report Publication Announcement (RPA), not the report itself (10-K). The document is announcing the release of the Annual Report.
2024-04-30 English
Observe Medical transfers Nordic distribution to Vingmed
Regulatory Filings Classification · 99% confidence The document announces a strategic decision by Observe Medical ASA to transfer its Nordic distribution operations to Vingmed. This involves a divestiture of a business segment and aligns with the company's objective to streamline operations and focus on international expansion. This type of announcement, concerning a significant business transaction or structural change that is not a standard financial report (like 10-K or IR) or a management change (MANG), best fits the category for Capital/Financing Update (CAP) as it relates to capital structure/business structure changes, or potentially Regulatory Filings (RNS) if no better fit exists. However, since it details a strategic divestiture/transfer of a business unit, which impacts the company's structure and future financing strategy, 'CAP' is a strong candidate. Given the options, 'CAP' covers financing activities and capital structure changes, which a major business divestiture falls under. It is not an earnings release (ER), a merger/takeover (TAR), or a general regulatory filing (RNS) as it is highly specific. I will classify it as CAP.
2024-04-18 English
Observe Medical transfers Nordic distribution to Vingmed
Regulatory Filings Classification · 100% confidence The document announces a strategic decision by Observe Medical ASA to transfer its Nordic distribution operations to Vingmed. This involves a divestiture of a business segment, which falls under corporate restructuring or significant business transactions. While it is not a formal M&A announcement (TAR), it is a significant corporate action related to business structure and operations. Since it is a direct announcement of a strategic business transfer/divestiture, it best fits the category for major corporate actions that aren't standard financial reports or management changes. Given the options, this type of strategic business realignment announcement, which is not a standard 10-K, ER, or IR, is often classified under general regulatory announcements or sometimes related to capital/financing if it significantly alters the business focus, but here it is a divestiture. It is not a standard M&A (TAR) as it's a transfer of internal operations, not a takeover bid. It is not a management change (MANG) or a dividend (DIV). It is a specific corporate event announcement. Since it is a strategic divestiture, it is most closely related to Capital/Financing Update (CAP) as it changes the operational structure, or potentially Regulatory Filings (RNS) as a catch-all for significant, non-standard announcements. Given the nature of transferring a business unit, it is a significant corporate event announcement. If a more specific category existed for 'Divestiture/Restructuring', that would be ideal. Lacking that, and noting it's a material announcement not covered by other specific financial reports, RNS (Regulatory Filings) is the most appropriate fallback for a significant, non-standard corporate disclosure, although CAP is a possibility if viewed as restructuring capital deployment. I will classify it as RNS as it is a general regulatory announcement about a major operational change.
2024-04-18 English
Observe Medical - CFO resignation
Board/Management Information Classification · 100% confidence The document explicitly announces the resignation of the Chief Financial Officer (CFO), Per Arne Nygård, and names the Interim CFO, Johan Fagerli. This directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and serves as a direct announcement, fitting the MANG category perfectly.
2024-03-21 English
Observe Medical - CFO resignation
Board/Management Information Classification · 100% confidence The document explicitly announces the resignation of the Chief Financial Officer (CFO), Per Arne Nygård, and the appointment of an Interim CFO, Johan Fagerli. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is short and focused solely on this personnel change, not a comprehensive financial report or a general regulatory filing.
2024-03-21 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.